Beyond monoclonal antibodies, lenalidomide has been found to reduce TNF-a, IL-6, and IL-1B levels and is approved for the treatment of the del(5q) subset of MDS—one of the most common cytogenetic alterations seen in MDS [79]. This evidence concerns the gene TNF and myelodysplastic syndrome.